Glaxo Seeks Indian Consumer Growth, Expanded Capacity

GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”

GlaxoSmithKline PLC’sbest-case scenario for growth in India includes building capacity for its consumer business there, CEO Andrew Witty says.

During a recent discussion Glaxo board members and executives conducted in New Delhi with a panel of Indian finance and pharmaceutical experts and media representatives, Witty said investing in large...

More from United Kingdom

More from Europe

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By 

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.